Objective: To assess the results of transurethral needle ablation (TUNA) (Prostiva®, Medtronic, France) performed in an ambulatory setting in men with lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH). Materials and Methods: A multicenter open-label study was conducted. Short-term success was defined by ability to leave the hospital on the evening of the intervention, and absence of rehospitalization due to complications during the first postoperative month. Sexual and urinary functions were evaluated by validated questionnaires. Results: The procedure was successful in 44/49 patients. Sexual and ejaculatory function was not affected or slightly improved in the majority of patients. Urinary parameters improved with a 32% decrease in the International Prostate Symptom Score. At 1 month postoperation, more than 80% of patients were satisfied, and 36/41 patients were prepared to undergo the procedure again if needed. Our study was limited by the short follow-up duration. Conclusions: TUNA can be successfully performed in an ambulatory setting under local and/or general anesthesia with a high level of patient satisfaction and a low short-term morbidity, especially on sexual function. Thus, the procedure is a suitable mini-invasive option for patients who cannot/do not want to take medical therapy or undergo invasive surgical procedures, or want to preserve their sexual function.

Keywords:
Ambulatory surgical procedures, Benign prostatic hyperplasia, Minimally invasive therapy, Transurethral needle ablation
1.
Oelke M, Bachmann A, Descazeaud A, et al: EAU guidelines on the treatment of non-neurogenic male LUTS. http://www.uroweb.org/gls/pdf/12_Male_LUTS.pdf. Accessed June 26th, 2011.
2.
de la Rosette J, Kortmann BM, Rossi C, et al: Long-term risk of re-treatment of patients using a-blockers for lower urinary tract symptoms. J Urol 2002;167:1734–1739.
3.
Masumori N, Hashimoto J, Itoh N, et al: Short-term efficacy and long-term compliance/treatment failure of the a1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Scand J Urol Nephrol 2007;41:422–429.
4.
Baazeem A, Elhilali MM: Surgical management of benign prostatic hyperplasia: current evidence. Nat Clin Pract Urol 2008;5:540–549.
5.
Bruskewitz R, Issa MM, Roehrborn CG, et al: A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 1998;159:1588–1594.
6.
Bouza C, López T, Magro A, et al: Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia. BMC Urol 2006;6:14.
7.
Boyle P, Robertson C, Vaughan ED, et al: A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia. BJU Int 2004;94:83–88.
8.
Hill B, Belville W, Bruskewitz R, et al: Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol 2004;171:2336–2340.
9.
Zlotta AR, Giannakopoulos X, Maehlum O, et al: Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 2003;44:89–93.
10.
Lourenco T, Pickard R, Vale L, et al: Minimally invasive treatments for benign prostatic enlargement: systematic review of randomised controlled trials. BMJ 2008;337:a1662.
11.
Muntener M, Aellig S, Kuettel R, et al: Sexual function after transurethral resection of the prostate (TURP): results of an independent prospective multicentre assessment of outcome. Eur Urol 2007;52:510–516.
12.
Kahn SA, Alphonse P, Tewari A, et al: An open study on the efficacy and safety of transurethral needle ablation of the prostate in treating symptomatic benign prostatic hyperplasia: the University of Florida experience. J Urol 1998;160:1695–1700.
13.
Steele GS, Sleep DJ: Transurethral needle ablation of the prostate: a urodynamic based study with 2-year follow up. J Urol 1997;158:1834–1838.
14.
Sullivan LD, Paterson RF, Gleave ME, et al: Early experience with transurethral needle ablation of large prostates. Can J Urol 1999;6:686–691.
15.
Harkaway RC, Issa MM: Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2006;9:204–214.
16.
Rosario DJ, Phillips JT, Chapple CR: Durability and cost-effectiveness of transurethral needle ablation of the prostate as an alternative to transurethral resection of the prostate when a-adrenergic antagonist therapy fails. J Urol 2007;177:1047–1051.
17.
Lourenco T, Armstrong N, N’Dow J, et al: Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement. Health Technol Assess 2008;12:1–515.
18.
National Institute of Diabetes and Digestive and Kidney Diseases: Minimally invasive surgical therapies (MIST) treatment consortium for benign prostatic hyperplasia (BPH). Available at: http://www.niddk.nih.gov/patient/mist/mist.htm. Accessed January 28th, 2010.
19.
Braun M, Mathers M, Bondarenko B, et al: Treatment of benign prostatic hyperplasia through transurethral needle ablation (TUNA™). Review of the literature and six years of clinical experience. Urol Int 2004; 72:32–39.
20.
Recommandations du Comité des Troubles Mictionnels de l’Homme sur l’Inscription à la Classification Commune des Actes Médicaux de la procédure TUNA]. September 2007. Available at: http://www.urofrance.org/nc/medecins/base-urofrance/article/html/recommandations-ctmh-sur-linscription-a-la-ccam-de-la-procedure-tuna-septembre-2007.html. Last accessed January 28th, 2010.
21.
Djavan B, Chapple C, Milani S, et al: State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004;64:1081–1088.
22.
Verhamme K, Dieleman JP, Bleumink GS, et al: Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. Eur Urol 2003;44:539–545.
23.
Nichol MB, Knight TK, Wu J, et al: Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol 2009;181:2214–2221.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.